剂量学驱动的放射性药物治疗个体化:证据与机遇
放射性药物治疗(RPT)临床应用日益广泛,但当前商业成功的177Lu药物采用固定给药方案未纳入患者剂量学。本文综述外照射放疗的肿瘤剂量-效应数据及RPT中肿瘤与正常器官吸收剂量的异质性,提示固定给药方案下相当比例患者相对器官耐受量被低估剂量,而剂量学指导的RPT规划可改善患者结局,并提出通过国家肿瘤剂量学登记推动剂量学常规收集以优化个体化治疗。
要点
- 固定给药方案未纳入患者剂量学,可能导致相当比例患者相对器官耐受量被低估剂量。
- 剂量学指导的RPT规划与患者结局改善相关,但吸收剂量测量变异性需通过标准化最小化。
- 剂量学数据常规收集于国家肿瘤剂量学登记有助于联合外照射、剂量递增与个体化优化。
核心结论
- RPT虽在快速发展但通常不可治愈,剂量学有望推动RPT从延长生存迈向治愈。
研究设计与样本
- 本文为综述,汇总外照射放疗肿瘤剂量-效应数据及当前RPT的肿瘤与正常器官吸收剂量异质性数据。
主要发现
- 许多常见癌症以精确递送的高剂量比低剂量治疗更有效。
- 采用先进剂量学方法显示当前RPT中肿瘤与正常器官吸收剂量存在异质性。
- 固定给药方案在确保安全时,相当数量患者相对器官耐受量被低估剂量。
- 数据强烈提示使用剂量学规划RPT的患者结局改善。
临床怎么用
- 临床实践中应日益收集剂量学数据并纳入国家肿瘤剂量学登记。
- 剂量学可用于联合外照射放疗、个体患者剂量递增与优化。
- 剂量学测量变异性应通过标准化来最小化。
局限性
- RPT吸收剂量测量存在变异性,需标准化以减小。
- 当剂量学提示初始周期后额外治疗回报递减时需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radiopharmaceutical therapy (RPT) is growing in clinical importance and utilization. First-generation RPTs such as 131I-tositumomab (Bexxar) radioimmunotherapy of lymphoma used simplified whole-body dosimetry in each patient to adjust administered activity levels to deal with patient-to-patient heterogeneity of radiation absorbed dose coefficients. In contrast, the commercially successful 177Lu-vipivotide tetraxetan and 177Lu-DOTATATE RPTs are given as one administered-activity-fits-all treatment approach not incorporating patient dosimetry. External beam radiotherapy dosimetry has been refined over nearly 100 years and is now routinely deployed in planning each therapy. This article reviews the tumor radiation dose-response data for external beam radiotherapy, showing many common cancers are more effectively treated with a precisely delivered higher rather than lower radiation dose. Data showing the heterogeneity of absorbed dose to tumors and normal organs using state-of-the-art dosimetry methods are reviewed for current RPTs, which strongly suggest a significant number of patients are underdosed, relative to organ tolerance, when assuring safety with one administered-activity-fits-all approaches. Data are presented which strongly suggest improved outcomes for patients in whom dosimetry is used to plan the RPT. Challenges in variability of measurement of radiation absorbed dose from RPT are highlighted, which are minimized by standardization. Cautions are identified when dosimetry suggests a diminished return on additional treatments after the initial cycles. A path forward is proposed in which dosimetry data are increasingly collected in clinical practice in a nascent National Oncologic Dosimetry Registry to aid in combination therapies with external beam radiotherapy, for dose escalation and optimization in individual patients and to better inform the field on the safety and longer-term tolerability of RPT. RPT is evolving rapidly but is generally not curative. We suggest dosimetry will be an important part of the path forward to move RPT from life-prolonging to curative.
引用
- Wahl RL, Dewaraja YK. Dosimetry-Driven Personalization of Radiopharmaceutical Therapies: Evidence and Opportunities. J Nucl Med. 2026. PMID: 42728103. doi:10.2967/jnumed.125.269488
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。